{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:05:27Z","timestamp":1788318327176,"version":"build-2803163510"},"reference-count":24,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Abrocitinib improved signs and symptoms of moderate\u2010to\u2010severe atopic dermatitis (AD) at Weeks 12 and 16 in phase 3 studies, with a manageable safety profile. Patient\u2010reported outcomes with long\u2010term abrocitinib treatment were not reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate patient\u2010reported outcomes with long\u2010term abrocitinib treatment in patients with moderate\u2010to\u2010severe AD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>JADE EXTEND (NCT03422822) is an ongoing, phase 3, long\u2010term extension study that enrolled patients from previous abrocitinib AD trials. This analysis includes patients from the phase 3 trials JADE MONO\u20101 (NCT03349060), JADE MONO\u20102 (NCT03575871) and JADE COMPARE (NCT03720470) who completed the full treatment period of placebo or abrocitinib (200 or 100\u2009mg once daily) and subsequently entered JADE EXTEND and were randomised to receive once\u2010daily abrocitinib 200 or 100\u2009mg. Patient\u2010reported endpoints to Week 48 included the proportion of patients who achieved Dermatology Life Quality Index (DLQI) scores of 0\/1 (no effect of AD on quality of life [QoL]) and a \u22654\u2010point improvement in Patient\u2010Oriented Eczema Measure (POEM) score (clinically meaningful improvement). Data cut\u2010off: April 22, 2020.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Baseline DLQI mean scores were 15.4 and 15.3 in the abrocitinib 200\u2010 and 100\u2010mg groups, respectively, which corresponded to a \u2018very large effect\u2019 on QoL; at Week 48, mean DLQI scores were lower with abrocitinib 200\u2009mg (4.6; \u2018small effect\u2019 on QoL) and abrocitinib 100\u2009mg (5.9; \u2018moderate effect\u2019 on QoL). Baseline POEM mean scores were 20.4 and 20.5 in the abrocitinib 200\u2010 and 100\u2010mg groups, respectively; at Week 48, mean POEM scores were 8.2 and 11.0. Week 48 patient\u2010reported responses with abrocitinib 200\u2009mg and abrocitinib 100\u2009mg were 44% and 34% for DLQI 0\/1, and 90% and 77% for a \u22654\u2010point reduction in POEM score.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients with moderate\u2010to\u2010severe AD, long\u2010term abrocitinib treatment resulted in clinically meaningful improvement in patient\u2010reported symptoms of AD, including QoL.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.19254","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T17:19:06Z","timestamp":1686849546000},"page":"2047-2055","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Abrocitinib effect on patient\u2010reported outcomes in patients with moderate\u2010to\u2010severe atopic dermatitis: Results from phase 3 studies, including the long\u2010term extension <scp>JADE EXTEND<\/scp> study"],"prefix":"10.1111","volume":"37","author":[{"given":"K.","family":"Reich","sequence":"first","affiliation":[{"name":"University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"},{"name":"Moonlake Immunotherapeutics AG  Zug Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"J. I.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"The George Washington University School of Medicine &amp; Health Sciences  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"K. A.","family":"Papp","sequence":"additional","affiliation":[{"name":"Alliance Clinical Trials and Probity Medical Research  Waterloo Ontario Canada"},{"name":"The University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0593-9925","authenticated-orcid":false,"given":"M.","family":"Deleuran","sequence":"additional","affiliation":[{"name":"Aarhus University Hospital  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Katoh","sequence":"additional","affiliation":[{"name":"Kyoto Prefectural University of Medicine  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-2057","authenticated-orcid":false,"given":"B.","family":"Strober","sequence":"additional","affiliation":[{"name":"Yale University  New Haven Connecticut USA"},{"name":"Central Connecticut Dermatology Research  Cromwell Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8452-667X","authenticated-orcid":false,"given":"L. A.","family":"Beck","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center  Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"de Bruin\u2010Weller","sequence":"additional","affiliation":[{"name":"UMC Utrecht  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Werfel","sequence":"additional","affiliation":[{"name":"Hannover Medical School  Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Biswas","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. D.","family":"DiBonaventura","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Chan","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Farooqui","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D UK Ltd.  Kent UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Kerkmann","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Clibborn","sequence":"additional","affiliation":[{"name":"Pfizer Ltd.  Tadworth Surrey UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.1572"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14116"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00488-x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16543"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19751"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb16953.x"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08832.x"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12437"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.055"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12590"},{"key":"e_1_2_10_13_1","unstructured":"Cibinqo (abrocitinib) tablets for oral use. Prescribing information Pfizer labs.2022."},{"key":"e_1_2_10_14_1","unstructured":"Pfizer Ltd.Cibinqo (abrocitinib) 100 mg film\u2010coated tablets. Summary of product characteristics.2021."},{"key":"e_1_2_10_15_1","volume-title":"CIBINQO\u00ae (abrocitinib). Summary of product characteristics","author":"European Medicines Agency","year":"2021"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019380"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2830"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16367"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-019-00373-y"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0029"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2190430"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.07.074"},{"key":"e_1_2_10_25_1","doi-asserted-by":"crossref","unstructured":"LangleyR ReichK SimpsonE WarrenRB CostanzoA SaekiH et al.Long\u2010term improvements in disease severity itch and quality of life after 3\u2009years of tralokinumab treatment in adults with moderate\u2010to\u2010severe atopic dermatitis. Presented at 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference Baltimore MD April 9\u201311 2022. Poster Presentation #241.","DOI":"10.26226\/m.63185c4d7e215f5e7f3850b5"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19254","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T13:14:26Z","timestamp":1711026866000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/jdv.19254"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19254","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]},"assertion":[{"value":"2023-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}